ConductScience.org, home

Trial · NCT07217340

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryStudy Retention7 weeks (baseline to post-intervention)Study retention as an outcome measure will be considered positive if ≥65% of participants complete data collection at both pre- and post-intervention.
PrimaryAcceptability of the Intervention7 weeks (throughout the intervention period)
Acceptability will be assessed through composite measures of adherence to different elements of the intervention. The intervention will be considered acceptable if at least 70% of participants attend a minimum of five sessions. Adherence to supportive practices (dream journaling and online SHEP engagement) will also be assessed. These components will be considered acceptable if ≥75% of participants engage in Virtual Reality at a rate of ≥65%.
PrimaryTolerability of Dream Yoga Virtual Reality7 weeks (after each VR session)
Tolerability will be assessed using the Simulator Sickness Questionnaire (SSQ), which measures nausea, oculomotor strain, and disorientation. The intervention will be considered tolerable if fewer than 20% of participants report severe simulator sickness or withdraw due to VR-related adverse effects. Additional safety will be monitored through adverse event logs.
PrimaryStudy Retention7 weeks (baseline to post-intervention)Feasibility will be assessed through study retention, defined as ≥65% of participants completing data collection at both pre- and post-intervention.
SecondaryFrequency of Lucid Dreaming7 weeks
Lucidity will be assessed with a composite of questionnaires at week 1 and measuring changes at week 7 and using self-reports of lucid dreams recorded in daily dream journals and/or nightly reports during the 7-week intervention. The outcome will be positive if one third of participants experience at least one lucid dream. Self-report Questionnaires: 1. Lucid Dreaming Skills Questionnaire (LUSK) 2. Lucid Dream Control-Specific Experiences (LDC-SE)
SecondaryAcceptability of the intervention7 weeks
Acceptability will also be measured with the Acceptability of Intervention Measure (AIM), a 4-item validated scale (1-5 Likert). The intervention will be considered acceptable if the mean AIM score is ≥4.
SecondaryFeasibility of the Intervention7 Week
Feasibility will be measured with the Feasibility of Intervention Measure (FIM), a 4-item validated scale (1-5 Likert). The intervention will be considered feasible if the mean FIM score is ≥4 ("agree" or "completely agree").
OtherChange in Cognitive Flexibility Scale Score7 weeks (baseline to post-intervention)Self-report measure assessing perceived ability to shift between thoughts and adapt to changing situations.
OtherChange in Generalized Anxiety Disorder Scale (GAD-7) Score7 weeks (baseline to post-intervention)
The Generalized Anxiety Disorder Scale - 7 item (GAD-7) is a self-report questionnaire used to assess anxiety symptoms over the past two weeks. Each item is rated on a 4-point Likert scale (0 = "not at all" to 3 = "nearly every day"). Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.
OtherSelf-referential Processing: Composite od Subjective and Neural Markers7 weeks
Self-referential processing will be assessed using a composite of subjective and neurophysiological measures. Subjective measures include the Mindful Attention Awareness Scale (MAAS), the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R), and the Nondual Awareness Dimensional Assessment (NADA) and Beck Cognitive Insight Scale. Neural activity associated with self-referential processing will be indexed by frontal midline theta power (4-7 Hz) during resting-state EEG. Increased frontal midline theta has been associated with internal attention, cognitive control, and self-related processing. A composite score may be computed via z-score standardization or used in exploratory correlation analyses. Higher mindfulness and nondual awareness scores, together with increased frontal midline theta, will be interpreted as indicators of enhanced self-referential regulation.
OtherChange in Probabilistic Reversal Learning Task Performance7 weeksBehavioral measure of adaptive learning and response shifting following feedback. Accuracy rate (proportion correct) and/or number of reversal errors will be assessed.
OtherChange in Stroop Task Performance7 weeksBehavioral measure of cognitive control and interference resolution. Reaction time in milliseconds and/or accuracy will be assessed.
OtherChange in PROMIS Anxiety Questionnaire Score7 weeks (baseline to post-intervention)
The Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Questionnaire is a self-report measure assessing anxiety symptoms. It generates a T-score standardized to the general U.S. population (mean = 50, SD = 10). Higher scores indicate more severe anxiety symptoms.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07217340/registered